OLIGOPIN®: publication in the Journal of Alzheimer’s disease

A study done by the Icahn School of Medicine at Mont Sinaï ( New York ) shows promising results for cognitive health

Alzheimer’s disease  is physiologically characterized by β and tau amyloid- related peptides aggregation which precipitates as fibrils in the brain (hippocampus and prefrontal cortex) and affects its correct functioning.

According to the publication, this two step study has highlighted that :

On the one hand (in vitro) :Oligopin®  prevents the generation of aggregation by stopping crosslinking of Aβ and tau amyloid- related soluble peptides

On the other hand (in vivo)Oligopin® metabolites ( methylated and glucuronide forms of catechin and epicatechin ) can cross the blood brain barrier and be active in the brain.

The authors of the study recommend considering Oligopin® as an interesting option to further  investigate prevention and treatment of Alzheimer condition

Journal of Alzheimer’s Disease 73 (2020) 1597–1606 DOI 10.3233/JAD-190543 IOS Press

OLIGOPIN®* is a natural pine bark extract, concentrated in  OPC ( Procyanidins )
For more information, please visit  www.theoriginalpinebarkextract.com or contact us : info@purextract.fr